☆ 4.6 Article

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Pembrolizumab Plus Chemotherapy in Squamous Non Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello et al.

Summary: This study provides five-year efficacy and safety outcomes for the treatment of previously untreated metastatic squamous non-small cell lung cancer patients. The results show that pembrolizumab plus chemotherapy significantly improves overall survival and progression-free survival compared to placebo plus chemotherapy. This study demonstrates that pembrolizumab plus chemotherapy is a first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina C. Garassino et al.

Summary: This study presents the 5-year outcomes of the KEYNOTE-189 study, which included previously untreated metastatic nonsquamous non-small-cell lung cancer patients. The results show that treatment with pembrolizumab plus pemetrexed-platinum significantly improves overall survival and progression-free survival compared to placebo plus pemetrexed-platinum. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care for previously untreated metastatic non-small-cell lung cancer patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks et al.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Oncology

Tumour-infiltrating lymphocytes: from prognosis to treatment selection

Koen Brummel et al.

Summary: Tumour-infiltrating lymphocytes (TILs) are crucial in anti-tumour immunity and have prognostic and predictive value. This review discusses the changing understanding of TILs' prognostic value over the past decade, as well as new insights on novel TIL subsets. It also explores the predictive significance of TILs in the era of immune therapy and the incorporation of these predictive capacities into clinical trials through new techniques like machine learning.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Review Pathology

Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists

Paul W. Harms et al.

Summary: Our understanding of human disease has evolved greatly in recent decades, particularly in the areas of immunology and cancer treatment. Advances in digital pathology have opened new avenues for studying the tumor microenvironment. Traditional tissue-based evaluations are limited in their ability to analyze complex quantitative data and multiple biomarkers, making multiplex staining techniques a promising alternative.

MODERN PATHOLOGY (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan et al.

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Martin Reck et al.

Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

Jeng-Shiuan Tsai et al.

Summary: This study compares the treatment efficacy of immune checkpoint inhibitors (ICIs) monotherapy with combination therapy in patients with advanced non-small cell lung cancer (NSCLC). The results show that combination therapy provides a better progression-free survival (PFS), especially in patients with low neutrophil-to-lymphocyte ratio (NLR).

PHARMACEUTICALS (2022)

Add to Collection

Article Oncology

Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer

Xiaojuan Lu et al.

Summary: This study selects platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for non-small cell lung cancer (NSCLC) patients, and finds that NLR is an independent prognostic factor.

ONCOLOGY LETTERS (2022)

Add to Collection

Article Immunology

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Giuseppe L. Banna et al.

Summary: A retrospective study of patients with advanced non-small cell lung cancer found that real-world progression-free survival with first-line chemoimmunotherapy is similar to clinical trial results. A high number of metastatic sites, squamous histology, and high systemic immuneinflammatory index were identified as adverse prognostic factors.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

Add to Collection

Article Oncology

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021,-189, and-407

Steven F. Powell et al.

Summary: This study retrospectively evaluated outcomes in patients with advanced NSCLC and found that first-line pembrolizumab plus chemotherapy was more effective than chemotherapy alone, regardless of baseline brain metastases, improving clinical outcomes and overall survival.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Tianyu Tang et al.

Summary: The tumor immune microenvironment plays a critical role in cancer immunity, and regulators within it could be promising targets for cancer immunotherapy, alone or in combination with immune checkpoint-targeting drugs.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

Add to Collection

Article Oncology

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Laura Mezquita et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

Po-Lan Su et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy

Katherine A. Scilla et al.

ONCOLOGIST (2017)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Surgery

Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer

Hua Zhang et al.

AMERICAN JOURNAL OF SURGERY (2015)

Add to Collection

Article Oncology

Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection

Yusuke Takahashi et al.

ANNALS OF SURGICAL ONCOLOGY (2015)

Add to Collection

Review Oncology

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Arnoud J. Templeton et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria

Temel Tirkes et al.

RADIOGRAPHICS (2013)

Add to Collection

Article Cardiac & Cardiovascular Systems

Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer

Khaled M. Sarraf et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2009)

Add to Collection

Review Multidisciplinary Sciences

Cancer-related inflammation

Alberto Mantovani et al.

NATURE (2008)

Add to Collection

Review Immunology

Cancer immunoediting from immune surveillance to immune escape

Ryungsa Kim et al.

IMMUNOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.